The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review
Since bevacizumab was first approved by the U.S. Food and Drug Administration as an anti-angiogenic therapy in 2004, angiogenesis-targeted therapy has been developed for various types of solid tumors. To date, ramucirumab and apatinib are clinically available as treatments for metastatic advanced ga...
Main Authors: | Izuma Nakayama, Daisuke Takahari |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/9/3226 |
Similar Items
-
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
by: Massimiliano Salati, et al.
Published: (2022-09-01) -
Current Targeted Therapy for Metastatic Colorectal Cancer
by: Tomokazu Ohishi, et al.
Published: (2023-01-01) -
A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer
by: Magdalena Skórzewska, et al.
Published: (2023-11-01) -
Application and challenge of immunotherapy in perioperative therapy of gastric cancer
by: XUE Chi, GAO Peng, ZHU Zhi, WANG Zhenning
Published: (2024-03-01) -
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
by: Shin Ariga
Published: (2023-05-01)